×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
|
Dashboard
Analyses
Exchange
Gaps
←
Home
/
Wiki
/
Mechanism: TDP-43 Proteinopathy in Amyotrophic Lateral Sclerosis
mechanism
3,471 words
KG: ent-dise-93f3d65f
Contents
TDP-43 Proteinopathy in Amyotrophic Lateral Sclerosis
⚙
Mechanism Info
Name
ent-dise-93f3d65f
No AI portrait yet
Generate portrait ✦
Knowledge Graph
Related Hypotheses (15)
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.38
Cryptic Exon Silencing Restoration
Score: 0.53
Cross-Seeding Prevention Strategy
Score: 0.69
Glycine-Rich Domain Competitive Inhibition
Score: 0.64
Stress Granule Phase Separation Modulators
Score: 0.72
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.79
Competitive APOE4 Domain Stabilization Peptides
Score: 0.78
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.76
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.76
APOE Isoform Expression Across Glial Subtypes
Score: 0.74
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.74
Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.72
APOE Isoform Conversion Therapy
Score: 0.72
Liquid-Liquid Phase Separation Modifier Therapy
Score: 0.55
RNA-Binding Competition Therapy for TDP-43 Cross-Seeding
Score: 0.47
Show 10 more
Related Analyses (30)
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
What is the therapeutic window between insufficient and toxi
neurodegeneration · completed
What determines the selectivity and efficiency of intercellu
neurodegeneration · completed
RNA binding protein dysregulation across ALS FTD AD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · completed
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · archived
Microglial subtypes in neurodegeneration — friend vs foe
neuroscience · archived
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · completed
How do non-cell autonomous effects of autophagy dysfunction
neurodegeneration · completed
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
Mitochondrial transfer between neurons and glia
neurodegeneration · completed
Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · completed
Mechanistic role of APOE in neurodegeneration
neurodegeneration · archived
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · archived
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
Show 25 more
Related Experiments (30)
cGAS/STING pathway activation by TDP-43-released mtDNA
exploratory · proposed · Score: 0.95
TDP-43 mitochondrial invasion and mtDNA release in iPSC moto
exploratory · proposed · Score: 0.90
TDP-43 mutant mouse model cGAS/STING pathway analysis
validation · proposed · Score: 0.90
TDP-43 mitochondrial invasion and DNA release via mPTP
exploratory · proposed · Score: 0.90
cGAS/STING pathway validation in TDP-43 mutant mice
validation · proposed · Score: 0.85
TDP-43 pathology prevalence and distribution in AD cases
exploratory · proposed · Score: 0.80
APOE4 association with TDP-43 pathology in AD
exploratory · proposed · Score: 0.75
Cognitive impact of TDP-43 pathology in AD patients
clinical · proposed · Score: 0.70
Viral and Post-Infectious Mechanisms in ALS — Experiment Des
clinical · proposed · Score: 0.40
s:** - Temporal analysis showing mitochondrial defects prece
falsification · proposed · Score: 0.40
Proposed experiment from debate on TDP-43 undergoes liquid-l
falsification · proposed · Score: 0.40
Proposed experiment from debate on TDP-43 undergoes liquid-l
falsification · proposed · Score: 0.40
Multiscale Computational Modeling of Protein Aggregation Kin
validation · proposed · Score: 0.40
Presymptomatic GRN Carrier Intervention Timing — Biomarker-G
clinical · proposed · Score: 0.40
Prion Strain Diversity and Selective Vulnerability in CJD
clinical · proposed · Score: 0.40
Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40
Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40
TDP-43 PET Ligand Development for FTD and ALS
clinical · proposed · Score: 0.40
ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40
Autophagy Enhancement Drug Screening for Neurodegeneration
clinical · proposed · Score: 0.40
C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Frontal and Temporal Lobe Selective Vulnerability in FTD — M
validation · proposed · Score: 0.40
FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation
clinical · proposed · Score: 0.40
s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40
ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40
Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40
TBK1-PAK1IP1-PAK1 signaling pathway analysis
exploratory · proposed · Score: 0.90
Endothelium-specific TBK1 knockdown in atherosclerosis model
validation · proposed · Score: 0.90
LC-MS/Western blot analysis of TBK1 in atherosclerotic arter
exploratory · proposed · Score: 0.80
Show 25 more
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)